Navigation Links
Resverlogix Notice of Conference Call & Webcast
Date:8/21/2008

TSX Exchange Symbol: RVX

CALGARY, Aug. 21 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that it will host a live teleconference on August 25, 2008 at 11:00 am MDT to provide a corporate update of the Company. Following the presentation there will be a live question and answer session.

The webcast can be accessed at the following link:

http://services.choruscall.com/links/resverlogix080825.html

Participants can also dial in for the conference call:

Dial information is as follows:

North American Toll Free Dial In: 1-800-319-4610

International Dial In: +1-604-638-5340

The webcast will be available on the Resverlogix website for replay for a period of 10 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jan Gray Joins Resverlogix Board of Directors
2. Resverlogixs Lead Drug Featured in Key Scientific Publication
3. Industry Leaders Select Resverlogixs RVX-208
4. /C O R R E C T I O N from Source -- Resverlogix Corp./
5. Resverlogix Notice of Conference Call & Webcast
6. Resverlogix Share Option Extension
7. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
8. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
9. Resverlogix is Presenting at IAS HDL Workshop
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 PAREXEL ... global clinical research organization , announced ... definitive agreement to acquire all of the ... a leading provider of specialized pharmacovigilance services, ... the collection, detection, assessment, monitoring, and prevention ...
(Date:3/25/2015)... pharmaceutical market is one of the most attractive ... absolute size, plus a growing economy and increasing government ... Monitor International. The Russian market is set to grow ... with growth estimates around 10-15% annually reaching an approximate ... About Green Cross Green Cross provides total ...
(Date:3/25/2015)... , March 25, 2015  S&P Capital ... Factual Stock Report coverage on Abattis Bioceuticals ... ATTBF; CSE: ATT): is a specialty biotechnology company ... cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, ... in North America . The ...
(Date:3/25/2015)... March 25, 2015  Point-of-Care Partners, a leading ... firm, has launched the ePrescribing State Law Capsule ... of ePrescribing regulatory requirements in all 50 states ... landscape continues to change rapidly, so we have ... industry, and ultimately patients, need," said Tony ...
Breaking Biology Technology:PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Point-of-Care Partners Launches the ePrescribing State Law Capsule 2
... COLUMBIA, Md., Aug. 11 BP and Martek Biosciences Corporation (Nasdaq: ... Development Agreement (JDA) to work on the production of microbial oils ... operational capabilities to advance the development of a step-change technology for ... Under the terms of the multi-year agreement, Martek and BP ...
... , QUEBEC CITY, Aug. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ... biopharmaceutical company focused on endocrinology and oncology, today reported financial and ... ended June 30, 2009. , , , ... - Two poster presentations at the American Association of Cancer, ...
... , SANTA MONICA, Calif. and LAS VEGAS, ... one of the largest umbilical cord blood stem cell preservation companies ... the life saving potential of stem cells to families nationwide and ... square foot facility in Las Vegas for conversion into a state-of-the-art ...
Cached Biology Technology:BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 3BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 4AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 2AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 3AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 4AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 5AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 6AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 7AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results 8Cord Blood America New Las Vegas Stem Cell Laboratory Scheduled for Opening in 4th Quarter 2009 2Cord Blood America New Las Vegas Stem Cell Laboratory Scheduled for Opening in 4th Quarter 2009 3
(Date:3/10/2015)... 10, 2015  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing ... wallet has been named the "Number One Best ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a ... home and lifestyle that have a unique function or ...
(Date:3/3/2015)... , March 3, 2015 Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... today announced the expansion of its relationship ... ("Fred Hutch") Clinical Research Division with ...
(Date:3/2/2015)... 2, 2015   Neurotechnology , a provider of ... SentiGaze Software Development Kit (SDK). The SentiGaze ... use off-the-shelf webcams to track eye movements and generate ... monitor. Heatmaps can be used for applications such as ... advertising. The SDK can also be used to develop ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... can cause congenital heart defects has been identified by a ... discovery could lead to new treatments for those affected by ... Princeton researchers focused on identifying and studying the gene in ... with other groups studying the genetics of mice and people. ...
... Parascript, LLC, the image analysis and pattern recognition ... Xpert was awarded best performance for forensic signature ... in Handwriting Recognition (ICFHR2010) in Kolkata, India, held ... seven participants representing a total of 10 offline ...
... insects and pathogens continue to become established in US forests ... a study published in the December 2010 issue of ... Juliann E. Aukema of the National Center for Ecological Analysis ... are being newly detected in US forests at a rate ...
Cached Biology News:Scientists find gene linked to congenital heart defect 2Scientists find gene linked to congenital heart defect 3Scientists find gene linked to congenital heart defect 4Parascript SignatureXpert Wins Forensic Signature Verification Competition 2Forest pests accumulating despite regulations 2
...
Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
...
... enhancements when used as directed, The ... designed to amplify the desired signal detected by Western ... with low expression., Membrane Enhancement Solution ... membrane; 1x solution; 250 ml, Membrane ...
Biology Products: